Focus Area: Presbyopia

Presbyopia is a natural part of the aging process in which the eye's lens gradually loses its flexibility, making it increasingly difficult to focus on close-up objects. This condition typically becomes noticeable in individuals around the age of 40 and progresses over time. It is one of the most prevalent vision conditions globally, affecting more than a billion people.

Traditionally, presbyopia has been managed through reading glasses, bifocals, progressive lenses, multifocal contact lenses, or surgical options. Orasis Pharmaceuticals has centered its research and development efforts on providing a pharmacological treatment that offers a convenient, non-surgical alternative delivered through eye drops.

Flagship Product: QLOSI (CSF-1)

Orasis Pharmaceuticals' primary product is QLOSI, an eye drop formulation developed for the treatment of presbyopia. Previously known during development as CSF-1, QLOSI is a preservative-free, low-dose pilocarpine ophthalmic solution designed to temporarily improve near vision in adults with presbyopia.

Key aspects of QLOSI include:

• It works by leveraging the pinhole effect, in which the pupil is slightly constricted (miosis) to increase the depth of focus, thereby improving near vision without significantly compromising distance vision.

• The formulation is preservative-free, which may help improve tolerability and reduce the potential for irritation associated with preserved eye drop products.

• It uses a low concentration of pilocarpine, a well-established compound in ophthalmology, in a proprietary formulation aimed at balancing efficacy and comfort.

• The product is intended to offer a convenient option for individuals seeking to reduce their reliance on reading glasses for everyday near-vision tasks.

QLOSI received U.S. Food and Drug Administration (FDA) approval for the treatment of presbyopia, marking a significant milestone for the company and representing an entry into the market of pharmacological presbyopia treatments.

Science and Technology

Orasis Pharmaceuticals' approach is grounded in the principle of pupil modulation to enhance near vision. By using a miotic agent to gently constrict the pupil, the company's eye drop increases the eye's depth of field, allowing patients to see nearby objects more clearly. This optical principle, often described as the pinhole effect, is a well-understood concept in optics that Orasis has applied to a pharmaceutical delivery format.

The company has invested significant effort in optimizing its formulation to achieve a balance between meaningful improvement in near vision and a favorable comfort and safety profile. The preservative-free nature of the product and the carefully calibrated dosage reflect the company's emphasis on both efficacy and patient experience.

Clinical Development

As a clinical-stage company, Orasis Pharmaceuticals has conducted rigorous clinical trials to evaluate the safety and efficacy of its presbyopia treatment. The company's clinical program included Phase 3 studies designed to assess how well the eye drop improved near vision in adults with presbyopia, as well as its tolerability and safety over time.

The successful completion of clinical trials and subsequent regulatory approval demonstrate the company's ability to advance a product from early research through to commercialization within the highly regulated pharmaceutical industry.

Company Profile and Location

Orasis Pharmaceuticals maintains connections to Israel, a country known for its robust ecosystem of medical technology, pharmaceutical innovation, and life sciences research. Israel has established itself as a global hub for MedTech and biotech startups, supported by strong academic institutions, research centers, and investment activity.

The company has attracted funding from investors interested in ophthalmic innovation, enabling it to progress its research and development pipeline and bring its presbyopia treatment to market.

Market and Patient Impact

The market for presbyopia treatments is substantial, given the large number of adults affected by the condition worldwide and the increasing average age of the global population. Many individuals with presbyopia seek alternatives to reading glasses for reasons of convenience, lifestyle, and personal preference.

By offering a pharmaceutical eye drop solution, Orasis Pharmaceuticals aims to serve patients who want a non-invasive, easy-to-use option that fits into their daily routines. The company's product provides an alternative that does not require carrying reading glasses or undergoing surgery, potentially improving quality of life for those who adopt it.

Summary

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to addressing presbyopia through innovative, non-surgical treatment options. Its flagship product, QLOSI (formerly CSF-1), is a preservative-free, low-dose pilocarpine eye drop developed to temporarily improve near vision in adults with presbyopia by leveraging the pinhole optical effect.

Through its focus on scientific research, careful formulation development, and rigorous clinical testing, the company has advanced a product from early development to regulatory approval. With ties to Israel's dynamic life sciences environment, Orasis Pharmaceuticals represents an example of MedTech innovation aimed at delivering practical, patient-friendly solutions for a widespread vision condition affecting a growing global population.